RE: Morning all4 May 2021 12:51
I'll keep saying it, he who laughs last Georgie boy.
Peer Group review
We have updated our peer group of London-listed drug developers with oncology assets
at a clinical or preclinical stage. ValiRx’s current market capitalisation is nearly fourfold
less than that of the peer-group median (£52.1m). Given that ValiRx has two clinical
stage assets as well as a preclinical programme, we maintain that this price discrepancy
is unjustified.
Peer-group comparison of London-listed drug developers with oncology assets at a clinical or preclinical stage
Name Ticker Mkt Cap
Median - 52.14
Valirx VAL LN 13.34
Hemogenyx Pharmaceuticals HEMO LN 12.85
Sareum Holdings SAR LN 74.87
Okyo Pharma OKYO LN 52.14
Tiziana Life Sciences TILS LN 166.39
Redx Pharma REDX LN 182.13
Scancell Holdings SCLP LN 169.16
Evgen Pharma EVG LN 21.72
Midatech Pharma MTPH LN 17.43